Global Peptide Therapeutics Market Report 2021: Market to Reach $47 Billion by 2027 – Innovative Segment to Account for $$28 Billion of the Total Market – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Peptide Therapeutics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.

Global Peptide Therapeutics Market to Reach $47 Billion by 2027

Amid the COVID-19 crisis, the global market for Peptide Therapeutics estimated at US$27.2 Billion in the year 2020, is projected to reach a revised size of US$47 Billion by 2027, growing at a CAGR of 8.1% over the period 2020-2027.

Innovative, one of the segments analyzed in the report, is projected to record 6.6% CAGR and reach US$28 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Generic segment is readjusted to a revised 10.6% CAGR for the next 7-year period.

The U.S. Market is Estimated at $7.4 Billion, While China is Forecast to Grow at 12.3% CAGR

The Peptide Therapeutics market in the U.S. is estimated at US$7.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$10.5 Billion by the year 2027 trailing a CAGR of 12.1% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.4% and 7.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.2% CAGR.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Influencer Market Insights

World Market Trajectories

Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS (Total 46 Featured):

AbbVie, Inc.

Advanced Accelerator Applications SA

Akashi Therapeutics, Inc.

Amgen, Inc.

Anthera Pharmaceuticals, Inc.

AstraZeneca PLC

Bachem AG

Bristol-Myers Squibb Company

Cardiorentis AG

Corden Pharma International GmbH

Debiopharm Group

Derma Sciences, Inc.

Eli Lilly and Company

F. Hoffmann-La Roche AG

GlaxoSmithKline PLC

Hanmi Pharmaceutical Co., Ltd.

Insmed, Inc.

Ipsen Group

Johnson & Johnson

Lonza Group AG

Mallinckrodt PLC

Merck & Co., Inc.

MolMed S.p.A.

Novartis AG

Novo Nordisk A/S

Nymox Pharmaceutical Corporation

PAR Pharmaceutical Companies, Inc.

PeptiDream Inc.

Pfizer, Inc.

PolyPeptide Group

Radius Health, Inc.

Repligen Corporation

Sanofi SA

SciClone Pharmaceuticals Holding Limited.

Shire PLC

Takeda Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Ltd.

The Medicines Company

X-GEN Pharmaceuticals, Inc.

Zealand Pharma A/S

Zydus Cadila

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

UNITED STATES

CANADA

JAPAN

CHINA

EUROPE

FRANCE

GERMANY

ITALY

UNITED KINGDOM

SPAIN

RUSSIA

REST OF EUROPE

ASIA-PACIFIC

AUSTRALIA

INDIA

SOUTH KOREA

REST OF ASIA-PACIFIC

LATIN AMERICA

ARGENTINA

BRAZIL

MEXICO

REST OF LATIN AMERICA

MIDDLE EAST

IRAN

ISRAEL

SAUDI ARABIA

UNITED ARAB EMIRATES

REST OF MIDDLE EAST

AFRICA

IV. COMPETITION

Total Companies Profiled: 46

For more information about this report visit https://www.researchandmarkets.com/r/x0hlr0
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.comFor E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900